Reuters logo
BRIEF-TESARO announces U.S. FDA approval of zejula for women with recurrent ovarian cancer
2017年3月27日 / 晚上8点01分 / 8 个月前

BRIEF-TESARO announces U.S. FDA approval of zejula for women with recurrent ovarian cancer

March 27 (Reuters) - TESARO Inc -

* TESARO announces U.S. FDA approval of zejula™ (niraparib) for women with recurrent ovarian cancer

* TESARO anticipates launching zejula in United States in late April

* Marketing authorisation application for niraparib is under review by European Medicines Agency Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below